Fallopian Tube Diseases: Clinical Trials

840 trials for Fallopian Tube Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

424 completed, 110 terminated, 97 recruiting, 78 active not recruiting. 384 Phase 2, 270 Phase 1, 111 Phase 3, 59 Not applicable, 18 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2384Completed 189, Terminated 58, Recruiting 44, Active not recruiting 40, Unknown 28, Withdrawn 15, Not yet recruiting 9, Suspended 1
Phase 1270Completed 143, Terminated 49, Recruiting 27, Active not recruiting 25, Withdrawn 11, Unknown 9, Not yet recruiting 4, Suspended 2
Phase 3111Completed 48, Recruiting 17, Unknown 16, Active not recruiting 14, Not yet recruiting 7, Terminated 6, Withdrawn 3
Not applicable59Completed 23, Recruiting 11, Unknown 9, Terminated 7, Withdrawn 6, Active not recruiting 2, Not yet recruiting 1
Early Phase 118Completed 9, Active not recruiting 4, Withdrawn 2, Suspended 1, Terminated 1, Unknown 1
Phase 42Active not recruiting 1, Completed 1

Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer
Phase 3Not yet recruitingDaiichi Sankyo6002027-03-312026-11-13
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
losartan, Paclitaxel - Platinum Resistant Ovarian Cancer
Phase 2Not yet recruitingMassachusetts General Hospital272027-02-012026-09-22
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer
Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingShanghai Gynecologic Oncology Group1302026-12-312026-11-17
A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.4202026-12-012026-11-09
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
Rina-S, Bevacizumab - Ovarian Cancer
Phase 3Not yet recruitingGenmab6022026-11-012026-10-05
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute532026-10-222026-10-01
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer
RecruitingAbbVie5002026-10-212026-10-27
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer
Phase 3RecruitingMerck Sharp & Dohme LLC6462026-10-072026-11-17
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
Routine-care metastasis-directed radiotherapy - Cervical Cancer, Gynecologic Cancer
RecruitingAffidea Nu-med Center of Oncological DIagnostics and Therapy5002026-10-062026-10-23
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 3Not yet recruitingBeOne Medicines6002026-10-012026-09-10
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Torvutatug samrotecan, Bevacizumab - Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer
Phase 3RecruitingAstraZeneca6002026-09-242026-10-16
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms
Phase 3RecruitingMerck Sharp & Dohme LLC8022026-09-182026-11-17
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Torvutatug samrotecan, Bevacizumab - Epithelial Ovarian Cancer
Phase 3RecruitingAstraZeneca9502026-09-162026-11-06
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma
Phase 2RecruitingUniversity of Washington262026-09-162026-11-02
Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients
Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III
RecruitingLatin American Cooperative Oncology Group3202026-09-082026-11-13
Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingUniversity of Colorado, Denver402026-09-012026-09-11
Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer
(Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab - Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers
Phase 1Not yet recruitingRebecca Arend242026-09-012026-10-15
Prospective Perioperative Clinical Registry for Women Undergoing Benign Gynecological Surgery
Standard Surgical Procedures for Benign Gynecological Conditions - Benign Gynecological Disease, Uterine Fibroids
Not yet recruitingIRCCS San Raffaele60002026-09-012026-08-19
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5) - High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences822026-07-232026-11-04
A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α(FRα)
Mirvetuximab Soravtansine (MIRV) - Ovarian Cancer, Fallopian Tube Cancers
Not yet recruitingNING LI-GYN4002026-07-202026-07-24

Showing 20 of 840. Sign in to see all of them.

Narrower conditions

Fallopian Tube Neoplasms (830)  ·  Ovarian Neoplasms (664)  ·  Carcinoma, Ovarian Epithelial (292)  ·  Endometrial Neoplasms (105)  ·  Uterine Cervical Neoplasms (76)  ·  Breast Neoplasms (62)  ·  Neoplasms (58)  ·  Peritoneal Neoplasms (53)  ·  Recurrence (39)  ·  Vulvar Neoplasms (39)  ·  Brenner Tumor (38)  ·  Carcinoma, Non-Small-Cell Lung (37)  ·  Vaginal Neoplasms (37)  ·  Stomach Neoplasms (34)  ·  Pancreatic Neoplasms (29)

Broader conditions

Female Urogenital Diseases (840)  ·  Female Urogenital Diseases and Pregnancy Complications (840)  ·  Genital Diseases (840)  ·  Urogenital Diseases (840)  ·  Adnexal Diseases (839)  ·  Genital Diseases, Female (836)  ·  Neoplasms by Site (826)  ·  Urogenital Neoplasms (826)  ·  Genital Neoplasms, Female (818)  ·  Gonadal Disorders (786)  ·  Endocrine System Diseases (785)  ·  Endocrine Gland Neoplasms (782)  ·  Neoplasms (776)  ·  Ovarian Diseases (774)

Interventions

Carboplatin (160)  ·  Paclitaxel (157)  ·  Bevacizumab (94)  ·  Gemcitabine (50)  ·  liposomal doxorubicin (49)  ·  Taxes (48)  ·  Topotecan (43)  ·  Cisplatin (35)  ·  pembrolizumab (34)  ·  Cyclophosphamide (29)  ·  olaparib (25)  ·  Disulfides (24)  ·  Immunoglobulin G (24)  ·  Specimen Handling (21)  ·  Docetaxel (20)

Sponsors

National Cancer Institute (NCI) (81)  ·  Gynecologic Oncology Group (41)  ·  M.D. Anderson Cancer Center (36)  ·  Memorial Sloan Kettering Cancer Center (28)  ·  Roswell Park Cancer Institute (16)  ·  Dana-Farber Cancer Institute (15)  ·  Mayo Clinic (15)  ·  Masonic Cancer Center, University of Minnesota (13)  ·  Shanghai Gynecologic Oncology Group (12)  ·  AGO Study Group (11)  ·  AbbVie (10)  ·  AstraZeneca (10)  ·  University Health Network, Toronto (9)  ·  Eli Lilly and Company (8)  ·  Merck Sharp & Dohme LLC (8)

Countries

United States (587)  ·  Canada (85)  ·  United Kingdom (75)  ·  Spain (69)  ·  China (58)  ·  Italy (57)  ·  France (54)  ·  Germany (54)  ·  Australia (52)  ·  Belgium (52)  ·  South Korea (52)  ·  Japan (32)  ·  Poland (26)  ·  Israel (24)  ·  Denmark (23)

Top investigators

Paul Sabbatini, MD (11)  ·  Emese Zsiros (6)  ·  Kunle Odunsi (6)  ·  Shannon N Westin (6)  ·  Ursula Matulonis, MD (6)  ·  Amit Oza (4)  ·  Amy D. Tiersten, MD (4)  ·  Angeles A Secord, MD (4)  ·  Dennis Chi, MD (4)

Results publications

PMID 37185961, PMID 37407274, PMID 32379297, PMID 35170751, PMID 21941283, PMID 35397664, PMID 16239238, PMID 16394300, PMID 19238149, PMID 19949018, PMID 20818904, PMID 22002018, PMID 22204724, PMID 22204725, PMID 23810467, PMID 25218906, PMID 26588236, PMID 31685558, PMID 36459691, PMID 36608308, PMID 37227734, PMID 37364223, PMID 40132910, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11181662, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12082455, PMID 12082456, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 12829663, PMID 12860964, PMID 14615449, PMID 14645425, PMID 14656276, PMID 14701743, PMID 15131031, PMID 15327776, PMID 15367671, PMID 15661234, PMID 15665856, PMID 15699482, PMID 1581961

NIH funding

U10CA027469 (38), U10CA180868 (35), U10CA101165 (10), UM1CA186709 (8), 2023 (7), N01CM62203 (6), P30CA016056 (6), N01CM62201 (5), N01CM62209 (5), P50CA136393 (5), U10CA032102 (5), 2017 (4), 2019 (4), 2025 (4), N01CM00071 (4)